Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
224 Leser
Artikel bewerten:
(1)

Monoclonal Antibodies Market to Reach $390.58 Bn, Globally at 10.2% CAGR by 2030: Says AMR

Rise in prevalence of various cancer types and increase in demand for cost-efficient biosimilar monoclonal antibodies, propel the growth of the global monoclonal antibodies market

PORTLAND, Ore., July 29, 2021 /PRNewswire/ -- According to the report the, global monoclonal antibodies market was pegged at $146.64 billion in 2020 and is estimated to reach $390.58 billion by 2030, manifesting a CAGR of 10.2% from 2021 to 2030.

Allied Market Research Logo

Rise in prevalence of various cancer types, increase in demand for cost-efficient biosimilar monoclonal antibodies, and surge in likelihood of epidemic or pandemic outbreaks fuel the growth of the global monoclonal antibodies market. However, low demand in underdeveloped countries hampers the growth to some extent. Nevertheless, several growth opportunities in emerging markets are expected to unlock worthwhile opportunities for the market.

Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/12154

COVID-19 scenario-

  • Increase in necessity for treatments available on a global scale has propelled rapid development of a large number of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralizing monoclonal antibodies (mAbs).
  • As a result, COVID-19 infection boosted growth and opportunities for the key players of the monoclonal antibodies market.

The human segment to dominate throughout the forecast period-

Based on source, the human segment held the highest market share in 2020, with more than two-fifths of the total revenue share. The segment, furthermore, is expected to maintain its dominance throughout the forecast period. In addition, the segment is also expected to manifest the fastest CAGR of 11.0% throughout the forecast period. This is attributed to increase in integration of advanced technology such as phage or yeast display, and transgenic mice, for human monoclonal antibodies generation, increase in usage for treatment of various chronic diseases, employment of advanced genetic engineering technology, increase in government support in infection control & management, and increase in number of product approvals.

The cancer segment to lead the trail throughout the forecast period-

Based on indication, the cancer segment accounted for the highest revenue share in 2020, holding nearly three-fifths of the total market share in 2020, and is anticipated to lead throughout 2030. The segment, furthermore, is also expected to exhibit the fastest CAGR of 10.7% throughout the forecast period. Increase in prevalence of cancer, and growth in adoption of monoclonal antibodies in cancer treatment drive the growth of the segment. In addition, increase in number of drug pipelines, rise in demand for biosimilar monoclonal antibodies, and surge in awareness level among the patient population regarding cancer treatment procedures further fuels the growth.

Enquiry for Short-term and Long-term Impacts of COVID-19 at: https://www.alliedmarketresearch.com/purchase-enquiry/12154

North America to hold the highest revenue share throughout the forecast period-

Based on region, North America held the major share in 2020, with more than two-fifths of the global market. This is due to rise in awareness levels among patients & physicians pertaining to the applications of monoclonal antibodies (mAb) therapy, and rise in approval of blockbuster mAbs for a variety of applications. On the other hand, the market across Asia-Pacific, on the other hand, would cite the fastest CAGR of 11.7% during the forecast period. This is owing to rise in research on biomedical and regenerative medicine, rise in awareness related to monoclonal antibodies, and availability of trained medical professionals.

Key market players-

  • Abbott Laboratories
  • AstraZeneca plc.
  • Amgen Inc.
  • Eli Lilly
  • GlaxoSmithKline Plc.
  • Bayer AG
  • Johnson & Johnson
  • Pfizer
  • Merck & Co. Inc
  • Novartis

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.

Similar Reports:

Enzymes Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

AI in Healthcare Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Mechanical Ventilators Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Influenza Vaccine Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Veterinary Imaging Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Biosensors Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Track and Trace Solutions Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

© 2021 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.